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Abstract
Inflammatory mediators have an important role in the pathogenesis of periodontal disease. One of the leading mediators
of the initiation of the pathological process is interleukin-1 (IL-1) – an endogenous pyrogen, a lymphocyte-activating factor.
Numerous pro-inflammatory effects of interleukin-1β (IL-1β ) occur in synergy with tumor necrosis factor alpha (TNF-α) and
interleukin-6 (IL-6), effects on hematopoiesis, participates in nonspecific anti-infective defense.
The objective of the study is to determine levels of interleukin-6 and tumor necrosis factor alpha (TNF-α) in patients with
hypertension II stage and generalized periodontitis of the II degree depending on the treatment method.
There were examined 30 patients with hypertension of the II stage and with generalized periodontitis of the II degree. Patients’
age ranged from 35 to 54 years. These patients were divided into two groups. The control group included 10 patients without
general somatic pathology and with healthy periodontitis of the same age.
The result of the analysis of tumor necrosis factor alpha (TNF-α) in patients in the first group before the treatment was
10.69±2.33 pg/ml. After the treatment this indicator was 6.97±1.57 pg/ml (p>0.1) in patients of the first group.
In patients of the second group the tumor necrosis factor alpha (TNF-α) was 9.49±2.2 pg/ml; after the treatment according to
the offered scheme this figure decreased up to 2.77±0.9 pg/ml (p<0.01). The level of tumor necrosis factor alpha (TNF-α) in
the control group was 1.5±0.77 pg/ml.
Interleukin-6 was 9.91±2.04 pg/ml before the treatment in the first group. After the treatment according to the standard
scheme, the level of interleukin-6 was 6.33±0.97 pg/ml (p>0.1). In the second group, before the treatment the level of
interleukin-6 was 9.65±2.41 pg/ml; after the treatment according to the offered scheme it was 2.62±0.5 pg/ml (p<0.01). In
the control group the interleukin-6 level was 2.24±0.51 pg/ml.
Analyzing the obtained results after the treatment in both groups we can conclude: after the treatment of generalized
periodontitis of the II degree in patients with hypertension of the II stage, indices of pro-inflammatory cytokines decreased
and ranged in normal limits; in patients from the second group (who received the offered scheme of treatment -including
medicines) indexes of pro-inflammatory cytokines were significantly lower than in patients with the standard treatment
scheme; the proposed scheme of treatment is more effective for treatment patients with generalized periodontitis of the II
degree and hypertension of the II stage.
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Problem statement and analysis of the
recent research
Inflammatory mediators play an important role in the patho-
genesis of periodontal disease. One of the leading mediators
of the initiation of the pathological process is interleukin-1 (IL-
1) – an endogenous pyrogen, a lymphocyte-activating factor
that has 2 forms: interleukin-1α (IL-1α) and interleukin-1β
(IL-1β ) encoded by different genes [1, 11]. Interleukin-1
(IL-1) is produced by activated macrophages, epithelial cells
(lymphocytes, fibroblasts, macrophages), endothelial cells,
glial cells, fibroblasts, keratinocytes [2, 3, 6, 8]. Cells of the
body cannot spontaneously synthesize interleukin-1 (IL-1),
but correspond to its production during the infection, the ac-
tion of microbial toxins, inflammatory agents, other cytokines,
activated components of the complement or blood coagulation
system. The value of interleukin-1 (IL-1) in the inflammatory
response is extremely important. Interleukin-1 (IL-1) stim-
ulates the production of adhesive molecules by endothelial
cells that promote the attachment of polymorphonuclear gran-
ulocytes and monocytes, as well as the mobilization of these
cells in the inflammatory site. Interleukin-1 (IL-1) induces
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synthesis of collagenase in fibroblasts. Interleukin-1 (IL-1)
stimulates bone resorption and delays the formation of colla-
gen and bone [12]. The level of interleukin-1 (IL-1) increases
significantly during the progression of chronic generalized
periodontitis in saliva and gum fluid [13].
Interleukin-1β (IL-1β ) is a strong cytokine that causes
bone resorption and is a mediator in the destruction of soft tis-
sue by stimulating the production of prostaglandins, induction
of collagenase, and other proteases. This cytokine has the abil-
ity to activate the synthesis of other cytokines: interleukin-2
(IL-2), interleukin-3 (IL-3), interleukin-5 (IL-5), interleukin-
6 (IL-6), interleukin-7 (IL -7), interleukin-8 (IL-8), tumor
necrosis factor alpha (TNF-α).
Numerous pro-inflammatory effects of interleukin-1β (IL-
1β ) occur in synergy with tumor necrosis factor alpha (TNF-
α) and interleukin-6 (IL-6), effects on hematopoiesis, partici-
pates in nonspecific anti-infective defense [3, 8].
Interleukin-6 (IL-6) is a multifunctional cytokine pro-
duced by macrophages, T- and B-lymphocytes, fibroblasts,
endothelial, epidermis and microglial cells, chondrocytes,
and osteocytes. Interleukin-6 (IL-6) stimulates the forma-
tion of B-cells, labrocytes, produces both lymphoid and non-
lymphoid cells, regulates acute-phase inflammatory response
and hematopoiesis [5, 8]. Interleukin-6 (IL-6) takes part in
activation of T-lymphocytes, regulates the synthesis of pro-
teins, which appear during acute phase of inflammation (fib-
rinogen, α-antichymotrypsin, acid glycoprotein, haptoglobin,
C-reactive protein) [7, 8, 9, 10].
Degranulation of cytokines and immunoglobulins in peri-
odontal tissues lead to destructive changes. Increased levels
of interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necro-
sis factor alpha (TNF-α) provoke processes and biochemi-
cal reactions that destroy periodontal tissues. Interleukin-1
(IL-1) and tumor necrosis factor alpha (TNF-α) activate os-
teoclasts, interleukin-1 (IL-1) provokes synthesis of collage-
nase, interleukin-6 (IL-6) activates differentiation of B cells
into plasma cells and the development of Ig G, which pro-
motes the fixation of the complement. Increased production
of interleukin-6 (IL-6) and interleukin-8 (IL-8) play an impor-
tant role in the pathogenesis of inflammation and resorption
of bone tissues [4]; chronic suppression of the production of
interleukin-2 (IL-2) lead to the development of autoimmune
disorders.
The objective of the study. The objective of the study is
to determine levels of interleukin-6 and tumor necrosis factor
alpha (TNF-α) in patients with hypertension of the II stage
and generalized periodontitis of the II degree depending on
the treatment method.
1. Materials and methods
There were examined 30 patients with hypertension of the
II stage and with generalized periodontitis of the II degree.
Patients’ age ranged from 35 to 54 years. These patients were
divided into two groups.
The first group received treatment according to the fol-
lowing scheme: irrigation of the oral cavity with solutions of
antiseptic agents (0.1% solution of chlorhexidine digluconate),
removal of soft plaque, ultrasonic removal of calculus, use of
“Metrogyl-denta” gel. The second group received the same
treatment as the first group, but with the inclusion of the fol-
lowing medicines (offered scheme): “Ca-D3 NICOMED” –
2 tablets per day (morning and evening, during 12 months);
Electrophoresis “Calcium Gluconate” for 10 sessions; “Pen-
toxifylline” – 1 tablet 3 times a day (during 30 days. The
medicine is prescribed as a course one time for three months
– 4 courses per year).
The control group included 10 patients of the same age
without general somatic pathology and with healthy periodon-
titis. The diagnosis of periodontal diseases was made ac-
cording to the anamnesis, clinical dental examination and
generally accepted additional methods of examination; and it
was classified according to M.F. Danylevsky (1994).
The obtained results were subjected to the variation-statistical
processing using statistical package “StatSoft 6.0”, classical
methods of variation statistics using averages and assessment
of their authenticity.
2. Results of the research and their
discussion
The result of the analysis of tumor necrosis factor alpha
(TNF-α) in patients of the first group before treatment was
10.69±2.33 pg/ml. After the treatment this indicator was
6.97±1.57 pg/ml (p>0.1) in patients of the first group.
In patients of the second group the tumor necrosis fac-
tor alpha (TNF-α) was 9.49±2.2 pg/ml; after the treatment
according to the offered scheme this figure decreased up to
2.77±0.9 pg/ml (p<0.01).
The level of tumor necrosis factor alpha (TNF-α) in the
control group was 1.5±0.77 pg/ml.
After the performed treatment the tumor necrosis factor
(TNF-α) decreased and ranged in the normal level in both
groups. The second group (where the improved scheme of the
treatment was used) the level of tumor necrosis factor (TNF-
α) was significantly lower than in the first group (standard
treatment).
Interleukin-6 before the treatment in the first group was
9.91±2.04 pg/ml. After the treatment according to the stan-
dard scheme, the level of interleukin-6 was 6.33±0.97 pg/ml
(p>0.1). In the second group, before the treatment the level
of interleukin-6 was 9.65±2.41 pg/ml; after the treatment
according to the offered scheme – 2.62±0.5 pg/ml (p<0.01).
In the control group the interleukin-6 level was 2.24±0.51
pg/ml.
Levels of pro-inflammatory cytokine interleukin-6 after
the treatment in both groups also returned to the normal levels;
the second group (with the offered scheme of treatment) level
of interleukin-6 was lower than in the first group (the standard
treatment) (table 1).
In the control group both indices were in the normal range.
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Table 1. Indeces of pro-inflammatory cytokines before and after the treatment
Group 1 Group 2 Control groupBefore treatment After treatment Before treatment After treatment
TNF-α 10.69±2.33 pg/ml 6.97±1.57 pg/ml 9.49±2.2 pg/ml 2.77±0.9 pg/ml 1.5±0.77 pg/ml
IL-6 9.91±2.04 pg/ml 6.33±0.97 pg/ml 9.65±2.41 pg/ml 2.62±0.5 pg/ml 2.24±0.51 pg/ml
Notes: In the Group 1 the reliability of the results of TNF-α (the factor of tumor necrosis alpha) before and after the treatment was p>0.1; in
the Group 2 the reliability of the results of TNF-α before and after the treatment was p<0.01; in the Group 1 the reliability of the results of
IL-6 (interleukin-6) before and after the treatment was p>0.1; in the Group 2, the reliability of the results of IL-6 before and after treatment
was p<0.01.
3. Conclusions
Analyzing the results after the treatment in both groups we
can conclude:
1. After the treatment of generalized periodontitis of the
II degree in patients with hypertension of the II stage
the indeces of pro-inflammatory cytokines decreased
and ranged in normal limits.
2. In patients of the second group (who received the of-
fered by us scheme of treatment – including medicines)
these indexes of pro-inflammatory cytokines were sig-
nificantly lower than in patients with the standard treat-
ment scheme.
3. The offered scheme of treatment is more effective for
treatment of patients with generalized periodontitis of
the II degree and hypertension of the II stage.
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